

—Original—

Inhibition of Inducible Nitric Oxide Synthase Attenuates Interleukin-1 β Induced Vascular Hyporeactivity in the Rabbit

Toru Shimizu, Atsuhiko Sakamoto and Ryo Ogawa

Department of Anesthesiology, Nippon Medical School

Abstract

Inhibition of nitric oxide (NO) synthesis has been indicated to improve vasopressor-responsiveness and to increase blood pressure in most septic models. However, numerous adverse effects of non-selective NO synthase (NOS) inhibition have been reported, and the effect of NOS inhibition on vascular responsiveness to vasodilators has not been well studied. Using an isometric tension measurement system of vascular rings, we evaluated the effects of an inducible NOS (iNOS) inhibitor, L-canavanine (L-CAN) and a non-selective NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) on interleukin-1 β (IL-1 β)-induced vascular hyporeactivity in the four different rabbit arteries.

Pretreatment of IL-1 β inhibited phenylephrine (Phe)-induced vascular constriction in the carotid artery (CA, 49% of control), pulmonary artery (PA, 66%), femoral artery (FA, 71%) and in the renal artery (RA, 83%). A combination of NOS inhibitors attenuated the vascular hyporeactivity to Phe in all arteries. Pretreatment of IL-1 β also inhibited acetylcholine (Ach)-induced vascular relaxation in FA, RA and CA. In PA, the rings were inversely constricted after Ach administration. The combination of IL-1 β with L-CAN, but not with L-NAME, attenuated the Ach-induced vasorelaxation to the control level in all arteries. These data suggest that the selective inhibition of iNOS attenuates the direct endothelial damage induced by IL-1 β *in vitro*. (J Nippon Med Sch 2002; 69: 149–153)

Key words: nitric oxide, interleukin-1 β , vascular reactivity, L-canavanine

Introduction

Septic shock is characterized by a systemic inflammatory response syndrome, hypotension with vasopressor-resistant systemic vasodilation, and the development of multiple organ failure and dysfunction. Sepsis leads to the elaboration of a self-amplifying cascade of pro- and anti-inflammatory cytokines and mediators, including a number of vasoactive substances, such as nitric oxide (NO),

endothelins, platelet activating factor, and leukotrienes¹.

NO appears to be an important mediator of impaired vascular responsiveness to vasoconstrictor agents in sepsis²⁻⁴. Inhibition of NO synthesis improves vasopressor-responsiveness and increases blood pressure in most septic animal models and in humans⁵⁻⁷; however, animal studies have revealed numerous adverse effects of non-selective NO synthase (NOS) inhibition^{3,8-11}. As shown in our previous study¹², a selective inducible NOS (iNOS) inhibitor, L-canavanine (L-CAN), attenuates vascular hypore-

Correspondence to Toru Shimizu, Department of Anesthesiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

E-mail: hopno-1@nms.ac.jp

Journal Website (<http://www.nms.ac.jp/jnms/>)

activity without hemodynamic instability in a rat septic shock model, suggesting that selective iNOS inhibition favorably affects hemodynamics and improves short-term survival when compared with either standard or non-selective NOS inhibitor support.

Although many previous reports focused on the effects of NOS inhibitors on vasopressor responsiveness, the effects of NOS inhibitors on vasodilator responsiveness and a comparison among the different kinds of vasculatures have not been extensively studied. In this study, we investigated the direct effects of iNOS and non-selective NOS on interleukin-1 β (IL-1 β)-induced vascular hyporeactivity using a rabbit vascular ring model, and also evaluated those effects on four different arteries.

Materials and Methods

With the approval of the Animal Experimental Ethical Review Committee, Nippon Medical School, twenty-three adult male Japanese White rabbits weighing between 2.5 and 3.0 kg were used. The animals were anesthetized with intravenous pentobarbital sodium (40 mg/kg) and pancuronium bromide (1~2 mg). They were intubated and mechanically ventilated with oxygen. Then 10 mg/kg of heparin sodium was given intravenously before the removal of arteries. The femoral (FA), renal (RA), carotid (CA), and pulmonary arteries (PA) were removed and placed in modified Krebs-Henseleit bicarbonate (KHB) solution (composition (mM): NaCl 119, KCl 4.75, CaCl₂ 2.54, MgSO₄ 1.19, KH₂PO₄ 1.19, NaHCO₃ 25, and glucose 11; pH was adjusted to 7.4). Each artery was dissected free of fat and connective tissue and cut into 3 mm length rings, taking special care not to damage the endothelial cell layers or stretch the vessels. Using an isometric tension measurement system (Easymagunus, UFER co. Ltd., Osaka), each ring was mounted between two stainless wires in an organ bath containing 5 ml of KHB solution. The KHB solution was gassed continuously with a mixture of 95% O₂ and 5% CO₂, and maintained at 37°C. Ring tension was recorded isometrically with a force-displacement transducer (TB-611 T, Nihon Kohden). The transducer was connected to

a computer to change the electrical signal into contracting and relaxing tensions, and the data were saved to disk (MacLab Chart/s, Macintosh 7200).

Effect of IL-1 β on vascular reactivity

The rings were stretched stepwise to adjust the resting tension to 2 g except for PA, which were stretched 1 g, and was equilibrated for 60 min by changing the bath fluids every 15 min. After attaining equilibrium, the rings were exposed to phenylephrine (Phe 10⁻⁶M) to induce contraction, which was taken as the 100% level for each ring throughout the experiment. From previous studies and preliminary studies on the response of Phe, the initial tensions of each ring mentioned above were determined. Five min after Phe administration, at which time maximal contraction was achieved, the rings were exposed to acetylcholine (Ach 10⁻⁶M). Relaxation caused by Ach was measured by the percent change in tension and then sodium nitroprusside (SNP 10⁻⁶M) was added. After the solution was washed and equilibrated for 60 min, the rings were exposed to human recombinant IL-1 β (25 ng/ml). Four hours after the administration of IL-1 β , the solution was washed and equilibrated for 60 min, and the same experimental procedure was repeated.

Effect of L-NAME and L-CAN on IL-1 β -induced vascular hyporeactivity

Arterial rings removed in the same way as described above were cut into two pairs of rings; one pair was exposed to NG-nitro-L-arginine methyl ester (L-NAME 10⁻⁴M) with IL-1 β , and the other was exposed to L-canavanine (L-CAN 10⁻³M) with IL-1 β . Four hours after the administration of the drugs, the same experiment was repeated. A previous study used endotoxin-treated rats that received either L-NAME (10 mg/kg/h) or L-CAN (100 mg/kg/h) to compare muscle intracellular pH and intracellular bioenergetic patterns *in vitro*¹³. Another study showed that high concentrations of L-CAN (2 \times 10⁻³M) were able to inhibit the activity of constitutive NOS (cNOS) *in vitro*¹⁴. From those experiments and our previous *in vivo* experiment, the doses of L-CAN and L-NAME used were 10⁻³M and 10⁻⁴M, respectively.

Data analysis

All data are expressed as mean \pm standard deviation of the mean. Statistical evaluation between the groups was performed with one-way factorial analysis of variance (ANOVA) using Scheffe's test to perform multiple comparisons. A p value of less than 0.05 was considered statistically significant.

Results

Phenylephrine-induced contraction (Fig. 1)

Fig. 1 shows the changes in Phe-induced contraction after treatment of four arteries. Four hours after the administration of IL-1 β , the Phe-induced contractions decreased in CA (49% of control), PA (66%), FA (71%) and in RA (83%). Additional NOS inhibitors (L-NAME, L-CAN) attenuated the vascular hyporeactivity to Phe in FA, CA and PA.

Ach and SNP-induced relaxation (Table 1)

In FA, RA and CA, the relaxation after administration of Ach was significantly inhibited by pretreatment of IL-1 β . In PA, the rings were inversely constricted after Ach administration. There were no significant differences in vasorelaxation between the rings with IL-1 β pretreatment, or with the combination of IL-1 β and L-NAME in any of the arteries. On the other hand, the combination with L-CAN attenuated the vasorelaxation to the control level in all arteries.

The relaxation after the addition of SNP showed no significant differences among the control and treatment groups in any of the arteries.

Discussion

In septic shock, bacterial lipopolysaccharide (LPS) activates the induction of a calcium-independent nitric oxide and stimulates macrophages, monocytes, endothelial cells to synthesize IL-1 β ¹⁵. Thus, IL-1 β has been implicated as a mediator of systemic response to infection. IL-1 β drives a cascade of mediators, which results in the loss of vascular tone and hypotension primarily through an increase in NO^{2,4,16}. Increased production of NO has been implicated as a mediator during septic shock




Fig. 1 Phenylephrine-induced contraction in femoral, renal, carotid and pulmonary arteries after treatment with IL-1 β and the effect of NOS inhibitors

■ control group: without IL- β or NOS inhibitors before the addition of phenylephrine, □ IL- β group: addition of IL-1 β alone before the addition of phenylephrine, ▨ L-NAME group: addition of IL-1 β and L-NAME before the addition of phenylephrine, ▩ L-CAN group: addition of IL-1 β and L-CAN before the addition of phenylephrine.

*p<0.05 compared with the control group.

and septic syndrome. NO is synthesized by two distinct NOS: cNOS and iNOS. LPS, IL-1 β and tumor necrosis factor- α induces a pronounced expression of iNOS mRNA in rat aortic smooth muscle cells¹⁷. Excessive production of iNOS results in an increase in NO, which may be a major contributing factor to vasodilatation during septic shock⁵.

L-arginine reversibly inhibits both forms of NOS, and has restored LPS-induced hypotension *in vivo*^{2,4-6}. Also the NOS inhibitors, N G-monomethyl-L-arginine (L-NMMA) and L-NAME have been reported to increase systemic vascular resistance and blood pressure in patients with septic shock⁷. Therefore, inhibition of NOS may represent a novel therapeutic approach towards managing hypotension in septic shock. However, L-NMMA produces a fall in cardiac output, which might worsen tissue perfusion⁸, increase renal vascular resistance and decrease renal blood flow^{3,9,10}. Furthermore, administration of L-NMMA to endotoxemic rats⁶ and rabbits¹¹ induces acute hypotension and death. These data suggest that non-selective NOS inhibitors inhibit

Table 1 Effects of L-NAME and L-CAN on Ach and SNP-induced vascular relaxation

	treatment	n	Ach(% of contraction)	SNP(% of contraction)
femoral artery	control	8	48.3 + 15.6	32.4 + 12.8
	IL-1 β	8	63.2 + 12.3 *	36.2 + 10.2
	L-NAME	12	66.8 + 6.7 *	31.6 + 9.5
	L-CAN	12	54.5 + 13.7	27.2 + 8.9
renal artery	control	9	42.5 + 5.1	3.1 + 1.5
	IL-1 β	9	68.2 + 6.0 *	7.8 + 3.4
	L-NAME	11	70.7 + 8.0 *	4.9 + 2.7
	L-CAN	11	43.6 + 4.6	4.2 + 1.6
carotid artery	control	8	40.9 + 7.4	4.3 + 2.3
	IL-1 β	8	77.1 + 22.0 *	7.9 + 3.9
	L-NAME	11	74.4 + 12.6 *	5.4 + 3.6
	L-CAN	11	48.3 + 12.9	4.0 + 2.5
pulmonary artery	control	9	47.2 + 9.6	13.3 + 4.9
	IL-1 β	9	132.9 + 26.5 *	15.8 + 11.9
	L-NAME	10	126.9 + 8.7 *	7.0 + 3.4
	L-CAN	10	47.6 + 15.5	9.0 + 6.4

control: without IL- β or NOS inhibitors before the addition of Phe

IL- β : addition of IL-1 β alone before the addition of Phe

L-NAME: addition of IL-1 β and L-NAME before the addition of Phe

L-CAN: addition of IL-1 β and L-CAN before the addition of Phe

* p < 0.05 compared with the control group.

IL-1 β inhibited vascular relaxation after administration of Ach, and the combination with L-CAN attenuated the vasorelaxation to the control level in all arteries.

not only iNOS, but also cNOS and physiological production of NO, which is not appropriate for the treatment of septic shock.

A selective blocker of iNOS, L-CAN, attenuates the effects of LPS on hemodynamics, and improves short term survival during rodent endotoxemia¹⁸. L-NAME, an inhibitor of cNOS and iNOS, enhances liver damage and tends to accelerate the time of death, but L-CAN significantly reduces 7 day mortality and has no deleterious effects in terms of organ damage¹⁹. In contrast to nitroarginine, L-CAN largely reverses LPS-induced vascular hyporeactivity in a dose-dependent manner in the rat aorta without any inhibition of vasodilator responses to Ach²⁰. Treatment with L-CAN reduces endotoxin-induced electron microscopic changes in the kidneys and lungs. Although *in vitro* selectivity is relatively modest compared with L-NAME, L-CAN does not modify blood pressure, carotid blood flow, or carotid vascular resistance in normal rats²¹.

In this study, the IL- β pretreatment rings were constricted after Ach administration in PA, while the rings were dilated in FA, RA and CA. This

suggests that the endothelium in PA was damaged more severely than in other arteries, and that Ach could stimulate receptors on vascular smooth muscle cells and caused vasoconstriction. An abnormal vascular response to Ach may represent a defect in the vasodilator function in the endothelium²². L-CAN attenuated vascular hyporeactivity even in serious disturbances of the endothelium, although L-NAME did not attenuate hyporeactivity. Previous studies reported that L-CAN only attenuated endotoxin-induced vascular hyporeactivity *in vivo*. In this study, L-CAN, a selective iNOS inhibitor, improved the endothelium disturbance of vasorelaxation *in vitro*, suggesting that inhibitors of iNOS may be beneficial in endotoxin-induced shock. Although the mechanism by which L-CAN protected against IL- β -induced endothelial damage *in vitro* cannot be deduced directly from our results, there are two possible explanations. First, decreasing NO production may reduce oxidative stress by slowing the formation of peroxynitrite, a highly reactive species formed from the reaction of NO with superoxide radicals²³. Secondly, decreasing NO production may reduce endothelial damage

by preventing a NO-mediated block of high-energy phosphate generation at the cellular level²⁴. A previous study revealed that L-CAN enhanced ATP concentration in various organs during rat endotoxic shock¹⁸.

In conclusion, IL-1 β inhibits the response of rabbit arteries, especially the pulmonary artery, to vasodilators as well as vasoconstrictor agents. L-CAN, but not L-NAME, attenuates the response to Ach to the control level in all the arteries. These data suggest that the selective inhibition of iNOS attenuates not only *in vivo* tissue perfusion, but also direct endothelial damage induced by IL-1 β *in vitro*.

References

1. Das UC: Critical advances in septicemia and septic shock. *Crit Care* 2000; 4: 290–296.
2. Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, Stoclet JC: The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. *Br J Pharmacol* 1991; 103: 1218–1224.
3. Perrella MA, Hildebrand FL, Jr., Margulies KB, Burnett JC, Jr.: Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function. *Am J Physiol* 1991; 261: R 323–328.
4. Thiernemann C, Vane J: Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat *in vivo*. *Eur J Pharmacol* 1990; 182: 591–595.
5. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991; 43: 109–142.
6. Nava E, Palmer RM, Moncada S: Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? *Lancet* 1991; 338: 1555–1557.
7. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. *Lancet* 1991; 338: 1557–1558.
8. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. *Cardiovasc Res* 1994; 28: 34–39.
9. Tolins JP, Raji L: Modulation of systemic blood pressure and renal haemodynamic responses by endothelium-derived relaxing factor (nitric oxide) "In Nitric Oxide from L-arginine: a Bioregulatory system" Moncada S, Higgs EA eds. 1990; pp 463–495, Elsevier Science, New York.
10. Walder CE, Thiernemann C, Vane JR: The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. *Br J Pharmacol* 1991; 102: 967–973.
11. Wright CE, Rees DD, Moncada S: Protective and pathological roles of nitric oxide in endotoxin shock. *Cardiovasc Res* 1992; 26: 48–57.
12. Cai M, Sakamoto A, Ogawa R: Inhibition of nitric oxide formation with L-canavanine attenuates endotoxin-induced vascular hyporeactivity in the rat. *Eur J Pharmacol* 1996; 295: 215–220.
13. Levy B, Valtier M, De Chillou C, Bollaert PE, Cane D, Mallie JP: Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. *Shock* 1999; 11: 98–103.
14. Schmidt HH, Zernikow B, Baeblich S, Bohme E: Basal and stimulated formation and release of L-arginine-derived nitrogen oxides from cultured endothelial cells. *J Pharmacol Exp Ther* 1990; 254: 591–597.
15. Dinarello CA: Biology of interleukin 1. *Faseb J* 1988; 2: 108–115.
16. Parratt JR: Nitric oxide in sepsis and endotoxaemia. *J Antimicrob Chemother* 1998; 41: 31–39.
17. Sirsjo A, Soderkvist P, Sundqvist T, Carlsson M, Ost M, Gidlof A: Different induction mechanisms of mRNA for inducible nitric oxide synthase in rat smooth muscle cells in culture and in aortic strips. *FEBS Lett* 1994; 338: 191–196.
18. Liaudet L, Fishman D, Markert M, Perret C, Feihl F: L-canavanine improves organ function and tissue adenosine triphosphate levels in rodent endotoxemia. *Am J Respir Crit Care Med* 1997; 155: 1643–1648.
19. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F: Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. *J Infect Dis* 1998; 177: 127–132.
20. Umans JG, Samsel RW: L-canavanine selectively augments contraction in aortas from endotoxemic rats. *Eur J Pharmacol* 1992; 210: 343–346.
21. Fatehi-Hassanabad Z, Burns H, Aughey EA, Paul A, Plevin R, Parratt JR, Furman BL: Effects of L-canavanine, an inhibitor of inducible nitric oxide synthase, on endotoxin mediated shock in rats. *Shock* 1996; 6: 194–200.
22. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med* 1986; 315: 1046–1051.
23. Szabo C: Alterations in nitric oxide production in various forms of circulatory shock. *New Horiz* 1995; 3: 2–32.
24. Salzman AL: Nitric oxide in the gut. *New Horiz* 1995; 3: 352–364.

(Received July 19, 2001)

(Accepted, August 28, 2001)